PE20050221A1 - Derivados de 3-(benzoilureido)-tiofeno sustituidos y procedimiento para su preparacion - Google Patents

Derivados de 3-(benzoilureido)-tiofeno sustituidos y procedimiento para su preparacion

Info

Publication number
PE20050221A1
PE20050221A1 PE2004000163A PE2004000163A PE20050221A1 PE 20050221 A1 PE20050221 A1 PE 20050221A1 PE 2004000163 A PE2004000163 A PE 2004000163A PE 2004000163 A PE2004000163 A PE 2004000163A PE 20050221 A1 PE20050221 A1 PE 20050221A1
Authority
PE
Peru
Prior art keywords
alkyl
phenyl
coo
benzoylureide
substituted
Prior art date
Application number
PE2004000163A
Other languages
English (en)
Inventor
Karl Schoenafinger
Elisabeth Defossa
Roedern Erich Von
Andreas Herling
Hans-Joerg Burger
Thomas Kalbunde
Karl-Ulrich Wendt
Original Assignee
Aventis Pharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Gmbh filed Critical Aventis Pharma Gmbh
Publication of PE20050221A1 publication Critical patent/PE20050221A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/28—Halogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/30—Hetero atoms other than halogen
    • C07D333/36—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/42—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms with nitro or nitroso radicals directly attached to ring carbon atoms
    • C07D333/44—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms with nitro or nitroso radicals directly attached to ring carbon atoms attached in position 5
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)

Abstract

SE REFIERE A DERIVADOS 3-(BENZOILUREIDO)-TIOFENO DE FORMULA (I), DONDE R5 ES F, Cl O Br; R1 ES H, F, Cl, Br; R2 ES H, F, Cl, Br, ALQUILO(C1-C6), CF3, OCF3, NO2, CN, O-ALQUILO(C1-C6), COOH, COO-ALQUILO(C1-C6), CONH2, ENTRE OTROS; R3 ES H, ALQUILO(C1-C6), COO-ALQUILO(C1-C6), SO2-ALQUILO(C1-C6), ALQUILO(C1-C6)-FENILO, FENILO, SO2-FENILO, EN DONDE EL ANILLO FENILO PUEDE ESTAR SUSTITUIDO; R4 ES H, ALQUILO(C1-C6), COO-ALQUILO(C1-C6), SO2-ALQUILO(C1-C6), SO2-PIPERIDINILO, SO2-PIPERAZINILO, ALQUILO-(C1-C6)-FENILO, DONDE LOS ANILLOS ESTAN OPCIONALMENTE SUSTITUIDOS; A ES UN RADICAL HETEROCICLO DE FORMULA 2a, 2b, 2c Y 3. SON COMPUESTOS PREFERIDOS: 1-[2-(5-AMINO-[1,3,4]OXDIAZOL-2-IL)-TIOFEN-3-IL]-3-(2-CLORO-4,5-DIFLURO-BENZOIL)-UREA, 1-(2-CLORO-4,5-DIFLUOR-BENZOIL)-3-[2-(5-OXO-4,5-DIHIDRO-[1,3,4]OXDIAZOL-2-IL)TIOFEN-3-IL]UREA, ENTRE OTROS. TAMBIEN SE REFIERE A UN PROCEDIMIENTO DE ELABORACION, Y UNA COMPOSICION FARMACEUTICA QUE CONTIENE AL COMPUESTO SOLO O ASOCIADO CON OTROS AGENTES ACTIVOS COMO AGENTES ANTIDIABETICOS, HIPOGLUCEMIANTES, INHIBIDORES DE HMGCoA-REDUCTASA, AGONISTAS PPAR GAMMA, ENTRE OTROS. ESTOS COMPUESTOS RETARDAN LA ACTIVIDAD DE LA GLICOGENOFOSFORILASA POR LO QUE SON APROPIADAS PARA DISMINUIR EL NIVEL DE GLUCOSA SANGUINEA, Y SON UTILES PARA EL TRATAMIENTO Y PREVENCION DE LA DIABETES TIPO II
PE2004000163A 2003-02-17 2004-02-17 Derivados de 3-(benzoilureido)-tiofeno sustituidos y procedimiento para su preparacion PE20050221A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE10306502A DE10306502B4 (de) 2003-02-17 2003-02-17 Substituierte 3-(Benzoylureido)-thiophenderivate und sie enthaltende Arzneimittel

Publications (1)

Publication Number Publication Date
PE20050221A1 true PE20050221A1 (es) 2005-04-04

Family

ID=32841675

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2004000163A PE20050221A1 (es) 2003-02-17 2004-02-17 Derivados de 3-(benzoilureido)-tiofeno sustituidos y procedimiento para su preparacion

Country Status (21)

Country Link
EP (1) EP1597247B1 (es)
JP (1) JP4589301B2 (es)
KR (1) KR20050105470A (es)
CN (1) CN1751036A (es)
AR (1) AR043179A1 (es)
AT (1) ATE402160T1 (es)
AU (1) AU2004212054A1 (es)
BR (1) BRPI0407552A (es)
CA (1) CA2516269A1 (es)
CO (1) CO5690549A2 (es)
DE (2) DE10306502B4 (es)
HR (1) HRP20050715A2 (es)
MA (1) MA27657A1 (es)
MX (1) MXPA05008331A (es)
NO (1) NO20054168L (es)
PE (1) PE20050221A1 (es)
PL (1) PL376753A1 (es)
RU (1) RU2005129109A (es)
TW (1) TW200505892A (es)
WO (1) WO2004072060A1 (es)
ZA (1) ZA200505487B (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7223786B2 (en) 2004-11-15 2007-05-29 Bristol-Myers Squibb Company 2-aminonaphthalene derivatives and related glycogen phosphorylase inhibitors
WO2006055462A1 (en) 2004-11-15 2006-05-26 Bristol-Myers Squibb Company 2-amino-4-functionalized tetralin derivatives and related glycogen phosphorylase inhibitors
WO2006053274A2 (en) 2004-11-15 2006-05-18 Bristol-Myers Squibb Company 2-amino-1-functionalized tetralin derivatives and related glycogen phosphorylase inhibitors
WO2006055463A2 (en) 2004-11-15 2006-05-26 Bristol-Myers Squibb Company 2-amino-3-functionalized tetralin derivatives and related glycogen phosphorylase inhibitors
WO2006113650A1 (en) * 2005-04-18 2006-10-26 Khan Saeed R Design and synthesis of novel tubulin polymerization inhibitors: bonzoylphenyluria (bpu) sulfur analogs
PE20110235A1 (es) 2006-05-04 2011-04-14 Boehringer Ingelheim Int Combinaciones farmaceuticas que comprenden linagliptina y metmorfina

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3034004A1 (de) * 1980-09-10 1982-04-22 Hoechst Ag, 6000 Frankfurt Sulfonylharnstoffe, verfahren zu ihrer herstellung, pharmazeutische praeparate auf basis dieser verbindungen und ihre verwendung
HUT48880A (en) * 1987-07-20 1989-07-28 Sandoz Ag Insecticides and acaricides comprising new n-benzoyl-n'-thienyl urea derivative as active ingredient and process for producing the active ingredients
DE10116768A1 (de) * 2001-04-04 2002-10-10 Aventis Pharma Gmbh Acylphenylharnstoffderivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
DE50102147D1 (de) * 2000-06-09 2004-06-03 Aventis Pharma Gmbh Acylphenylharnstoffderivate, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
PE20021091A1 (es) * 2001-05-25 2003-02-04 Aventis Pharma Gmbh Derivados de fenilurea sustituidos con carbonamida y procedimiento para su preparacion
IL164249A0 (en) * 2002-04-11 2005-12-18 Aventis Pharma Gmbh Acyl-3-carboxphenylurea derivatives, processes forpreparing them and their use
DE10215908B4 (de) * 2002-04-11 2005-08-18 Aventis Pharma Deutschland Gmbh Acyl-3-carboxyphenyl-harnstoffderivate und deren Verwendung als Arzneimittel
DE10225635C1 (de) * 2002-06-07 2003-12-24 Aventis Pharma Gmbh N-Benzoylureido-Zimtsäurederivate, Verfahren zu deren Herstellung und deren Verwendung
WO2004007437A1 (de) * 2002-07-11 2004-01-22 Aventis Pharma Deutschland Gmbh Harnstoff- und urethan-substituierte acylharnstoffe, verfahren zu deren herstellung und deren verwendung als arzneimittel
NZ537603A (en) * 2002-07-12 2006-09-29 Sanofi Aventis Deutschland Heterocyclically substituted benzoylureas, method for their production and their use as medicaments
DE10246434B4 (de) * 2002-10-04 2005-08-04 Aventis Pharma Deutschland Gmbh Carboxyalkoxy-substituierte Acyl-carboxyphenyl-harnstoffderivate und ihre Verwendung als Arzneimittel

Also Published As

Publication number Publication date
RU2005129109A (ru) 2006-01-27
CN1751036A (zh) 2006-03-22
CA2516269A1 (en) 2004-08-26
NO20054168L (no) 2005-11-11
AR043179A1 (es) 2005-07-20
AU2004212054A1 (en) 2004-08-26
KR20050105470A (ko) 2005-11-04
NO20054168D0 (no) 2005-09-07
EP1597247A1 (de) 2005-11-23
CO5690549A2 (es) 2006-10-31
MA27657A1 (fr) 2005-12-01
EP1597247B1 (de) 2008-07-23
BRPI0407552A (pt) 2006-02-14
JP2006517933A (ja) 2006-08-03
TW200505892A (en) 2005-02-16
PL376753A1 (pl) 2006-01-09
DE10306502B4 (de) 2005-03-17
WO2004072060A1 (de) 2004-08-26
DE502004007668D1 (de) 2008-09-04
DE10306502A1 (de) 2004-09-09
JP4589301B2 (ja) 2010-12-01
HRP20050715A2 (en) 2006-09-30
ATE402160T1 (de) 2008-08-15
MXPA05008331A (es) 2005-09-30
ZA200505487B (en) 2006-08-30

Similar Documents

Publication Publication Date Title
RU2363700C2 (ru) Производные хинуклидина и фармацевтические композиции, содержащие их
PE20080906A1 (es) Derivados heteroarilo como inhibidores de citocina
ATE368653T1 (de) Oxazolylaryloxyessigsäure derivate und ihre verwendung als ppar agonisten
HRP20171838T4 (hr) Novi spojevi s inhibicijskom aktivnošću protiv transportera glukoze ovisnog o natriju
NO20060823L (no) Benzimidazol, benztiazol og benzoksazol derivater og deres anvendelse som LTA4H modulatorer
PE20040898A1 (es) Nuevos compuestos derivados de pirimidina
PE20070218A1 (es) COMPUESTOS DE CICLOALQUILO AMINO-HIDANTOINA Y USO DE ESTOS PARA LA MODULACION DE ß-SECRETASA
AR056574A1 (es) Derivados de pirazol, composiciones que contienen dichos compuestos y procedimientos de uso
PE20040649A1 (es) Procedimiento para la preparacion de benzoilureas heterociclicamente sustituidas
RU2011106374A (ru) Циклические ингибиторы 11бета-гидроксистероид-дегидрогеназы 1
RU2203274C2 (ru) Спироциклические ингибиторы металлопротеаз
AR032781A1 (es) Amidas ariladas de acidos furan- y tiofencarboxilicos, composiciones farmaceuticas, su utilizacion para la preparacion de medicamento como tambien las composiciones farmaceuticas que las contienen
CO5611139A2 (es) Pirimidinas aril sustituidas y el uso de las mismas
PE20070545A1 (es) Derivados de fenil-[1,2,4]-oxadiazol-5-ona con grupo fenilo como agentes moduladores de ppar, composiciones farmaceuticas que los contienen y procedimientos para su preparacion
PE20051173A1 (es) Compuestos azabiciclico (3.1.0) hexanos como moduladores de receptores de dopamina d3
PE20070829A1 (es) Inhibidores cetp heterociclicos
NO20085169L (no) Krystallinske solvater og komplekser av (1S)-1,5-anhydro-L-C- (3-((fenyl)metyl)fenyl)-D-glucitol derivater med aminosyrer som SGLT2-inhibitorer for behandling av diabetes
CO5640098A2 (es) Acidos biariloximetilaren-carboxilicos
PE20081704A1 (es) Derivados de azacicloalcanos como inhibidores de estearoil-coenzima a delta-9 desaturasa
PE20060729A1 (es) Compuestos heterociclicos como moduladores o inhibidores de la actividad de miostatina
NO20101069L (no) Anvendelse av visse NMDA-affinitetsantagonister som antidepressiva
CA2503117A1 (en) Substituted 4-alkoxyoxazol derivatives as ppar agonists
PE20080267A1 (es) Compuestos triarilicos y sus derivados
PE20061155A1 (es) Derivados de indolinona como agentes para el tratamiento o la prevencion de enfermedades fibroticas
PE20030718A1 (es) Lactamas como antagonistas de taquiquininas

Legal Events

Date Code Title Description
FD Application declared void or lapsed